drugset / Trial / NCT04068831
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
Timeline
- Start
- 2019-08-22
- Primary completion
- 2023-12-06
- Completion
- 2023-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 800 mg | — |
| Subject | Talazoparib | Small molecule | 1 mg | — |